Stock

Tesla, Eli Lilly lead market cap stock movers on Monday

Monday’s market has seen significant movements in various stocks, with mega-caps like Tesla Motors (NASDAQ:TSLA) and Eli Lilly And Co (NYSE:LLY) experiencing notable changes. Large-caps such as Palantir Technologies Inc (NYSE:PLTR) and Dollar Tree Inc (NASDAQ:DLTR) also showed considerable fluctuations. Here’s a look at some of the most impactful stock movers across the market cap spectrum, from mega-caps to small caps, during intra-day trading.

Mega-Cap Movers (Market Cap $200B+):

Tesla Motors (TSLA): +8.14%
NVIDIA Corp (NASDAQ:NVDA); NVIDIA (NVDA) Customers Worry Snag with New AI Chip – The Information: -1.21%
Eli Lilly And Co (LLY): -4.22%
Adv Micro Device (NASDAQ:AMD): +3.83%

Large-Cap Stock Movers (Market Cap $10B-$200B):

Mobileye Global (NASDAQ:MBLY): +10.01%
Super Micro Compu (NASDAQ:SMCI): +8.07%
Robinhood Markets (NASDAQ:HOOD); Robinhood shares upgraded to Buy, price target set on cryptocurrency offerings: +6.57%
Dollar Tree Inc (DLTR): +5.18%
Palantir Technologies Inc (PLTR): -6.87%
Uber Technologies Inc (NYSE:UBER): -6.1%
Natera Inc (NASDAQ:NTRA): +5.52%
Affirm Holdings (NASDAQ:AFRM); Priceline Selects Affirm as Pay-Over-Time Provider for Priceline Partner Solutions: +7.89%

Mid-Cap Stock Movers (Market Cap $2B-$10B):

dMY Technology Group III (IONQ): -20.73%
AltC Acquisition (OKLO): +13.11%
Twist Bioscience Corporation (NASDAQ:TWST); Twist Bioscience Announces Fiscal 2024 Fourth Quarter and Full Year Financial Results: +12.33%
Bloom Energy Corp (NYSE:BE): +10.88%
Oaktree Acquisition Corp (NYSE:HIMS); Hims & Hers Appoints Tenured Pharmaceutical (TADAWUL:2070), Regulatory, and Quality Experts to Key Leadership Positions: +9.03%
TSLL (TSLL): +16.03%
BITX (BITX): -1.55%
Marathon Pa (MARA); MARA Holdings to offer $700 million in convertible notes: -4.75%
Reinvent Technology Partners Y (AUR): +12.53%
Zeekr Intelligent Technology ADR (ZK): +6.51%

Small-Cap Stock Movers (Market Cap $300M-$2B):

Aquinox Pha (NASDAQ:NGNE); Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome: -37.31%
Quantum (NASDAQ:QMCO) Computing OTC (QUBT): -19.3%
Innodata Isogen (INOD): +17.55%
TimefireVR (RCAT): +15.76%
Amplify YieldShr Oil Hdg MLP Incm (AMLX): +15.44%
TSLT (TSLT): +14.75%
Kingsoft Cloud Holdings Ltd (KC): -13.56%
Destiny Tech100 (DXYZ): +14.92%
Gores Metropoulos Inc (NASDAQ:LAZR): -10.93%
Frontier Group Holdings (NASDAQ:ULCC): -12.13%

For real-time, market-moving news, join Investing Pro.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

This post appeared first on investing.com

You May Also Like

Economy

A U.N. human rights group confirmed Hamas’ leader in Lebanon, who was recently killed by Israeli strikes, was their employee.  Fateh Sherif was killed...

Investing

Astron (ASX:ATR) and Energy Fuels (TSX:EFR,NYSEAMERICAN:UUUU) have completed the establishment of a joint venture to advance the Australia-based Donald rare earths and mineral sands...

Editor's Pick

Sister Stephanie Schmidt had a hunch about what her fellow nuns would discuss over dinner at their Erie, Pennsylvania, monastery on Wednesday night. The...

Latest News

Boeing machinists voted against a new labor deal that included 35% wage increases over four years, their union said Wednesday, extending a more than five-week strike that has halted...

Disclaimer: balanceandcharge.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2025 balanceandcharge.com

Exit mobile version